PRA Health Sciences (PRAH) Raised to Strong-Buy at BidaskClub

PRA Health Sciences (NASDAQ:PRAH) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Thursday.

Other research analysts have also issued research reports about the company. SunTrust Banks upped their price objective on PRA Health Sciences to $120.00 and gave the stock a “buy” rating in a report on Monday, November 5th. KeyCorp reaffirmed a “buy” rating and set a $115.00 price objective on shares of PRA Health Sciences in a report on Thursday, August 2nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $115.00 price objective on shares of PRA Health Sciences in a report on Friday, July 20th. Mizuho set a $100.00 price objective on PRA Health Sciences and gave the stock a “hold” rating in a report on Monday, August 6th. Finally, Evercore ISI began coverage on PRA Health Sciences in a report on Thursday, October 4th. They set an “inline” rating and a $120.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $111.50.

Shares of PRAH stock opened at $106.43 on Thursday. PRA Health Sciences has a 1-year low of $76.39 and a 1-year high of $112.88. The firm has a market cap of $6.71 billion, a P/E ratio of 33.26, a price-to-earnings-growth ratio of 1.51 and a beta of 0.73. The company has a current ratio of 0.89, a quick ratio of 0.93 and a debt-to-equity ratio of 1.22.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Wednesday, October 31st. The medical research company reported $1.13 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.07 by $0.06. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The firm had revenue of $717.60 million for the quarter, compared to analyst estimates of $729.63 million. During the same quarter in the prior year, the company posted $0.88 earnings per share. PRA Health Sciences’s quarterly revenue was up 23.3% on a year-over-year basis. Equities analysts predict that PRA Health Sciences will post 3.93 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. CIBC World Markets Inc. acquired a new stake in PRA Health Sciences in the third quarter valued at $816,000. FMR LLC grew its holdings in PRA Health Sciences by 1.0% in the third quarter. FMR LLC now owns 2,317,493 shares of the medical research company’s stock valued at $255,365,000 after purchasing an additional 21,818 shares during the last quarter. American International Group Inc. grew its holdings in PRA Health Sciences by 15.6% in the third quarter. American International Group Inc. now owns 118,096 shares of the medical research company’s stock valued at $13,013,000 after purchasing an additional 15,938 shares during the last quarter. BlackRock Inc. grew its holdings in PRA Health Sciences by 11.9% in the third quarter. BlackRock Inc. now owns 6,074,310 shares of the medical research company’s stock valued at $669,328,000 after purchasing an additional 647,401 shares during the last quarter. Finally, Twin Tree Management LP grew its holdings in PRA Health Sciences by 59.7% in the third quarter. Twin Tree Management LP now owns 2,058 shares of the medical research company’s stock valued at $227,000 after purchasing an additional 769 shares during the last quarter. 98.82% of the stock is currently owned by institutional investors.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Recommended Story: Call Option

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply